BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies
BioNTech SE American Depositary Share · Now $95.95
+9.3% in 7d after detection
Post-detection moves
1h
—
1d
+2.9%
3d
+5.0%
7d
+9.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS